Entry Rationale
We are considering an entry as the stock price is showing an upward trend towards the resistance level of $104.40, supported by a strong catalyst of an upward revision in revenue outlook.
Twist Bioscience signals $123M-$124M Q4 revenue as fiscal 2026 outlook rises to $456M-$457M
Twist Bioscience raised its fiscal year 2026 outlook to $456 million to $457 million, projecting fourth-quarter revenue of $123 million to $124 million.
We are considering an entry as the stock price is showing an upward trend towards the resistance level of $104.40, supported by a strong catalyst of an upward revision in revenue outlook.
If the stock price rises towards the resistance level of $104.40, I will take profits, and if the support level of $82.80 is breached, I will cut losses.
The RSI(14) is at a neutral level of 51.4, and the moving averages are in a positive alignment. The trading volume is 1.10 times the 20-day average, and the recent 7-day volatility is -2.8%.
There are past similar success cases with overlapping revenue growth keywords, including BLZE (2026-08-04), TWST (2026-08-05), and ENTG (2026-08-05).
The key positive factor of an upward revision in revenue outlook was accurately captured, leading to a well-read trend in stock price increase; however, the risk of equity dilution due to the offering was overlooked, resulting in an actual return of 15.1%, significantly exceeding the forecasted return of 4.5%.
Even with strong positive factors, stock price volatility may increase in the event of an offering announcement, so it is necessary to analyze the risks associated with the nature of the announcement more closely and develop a response strategy.